305 related articles for article (PubMed ID: 24037523)
1. Genetic inactivation or pharmacological inhibition of Pdk1 delays development and inhibits metastasis of Braf(V600E)::Pten(-/-) melanoma.
Scortegagna M; Ruller C; Feng Y; Lazova R; Kluger H; Li JL; De SK; Rickert R; Pellecchia M; Bosenberg M; Ronai ZA
Oncogene; 2014 Aug; 33(34):4330-9. PubMed ID: 24037523
[TBL] [Abstract][Full Text] [Related]
2. PDK1 and SGK3 Contribute to the Growth of BRAF-Mutant Melanomas and Are Potential Therapeutic Targets.
Scortegagna M; Lau E; Zhang T; Feng Y; Sereduk C; Yin H; De SK; Meeth K; Platt JT; Langdon CG; Halaban R; Pellecchia M; Davies MA; Brown K; Stern DF; Bosenberg M; Ronai ZA
Cancer Res; 2015 Apr; 75(7):1399-412. PubMed ID: 25712345
[TBL] [Abstract][Full Text] [Related]
3. Characterization of GSK2334470, a novel and highly specific inhibitor of PDK1.
Najafov A; Sommer EM; Axten JM; Deyoung MP; Alessi DR
Biochem J; 2011 Jan; 433(2):357-69. PubMed ID: 21087210
[TBL] [Abstract][Full Text] [Related]
4. β-catenin signaling controls metastasis in Braf-activated Pten-deficient melanomas.
Damsky WE; Curley DP; Santhanakrishnan M; Rosenbaum LE; Platt JT; Gould Rothberg BE; Taketo MM; Dankort D; Rimm DL; McMahon M; Bosenberg M
Cancer Cell; 2011 Dec; 20(6):741-54. PubMed ID: 22172720
[TBL] [Abstract][Full Text] [Related]
5. Abrogation of BRAFV600E-induced senescence by PI3K pathway activation contributes to melanomagenesis.
Vredeveld LC; Possik PA; Smit MA; Meissl K; Michaloglou C; Horlings HM; Ajouaou A; Kortman PC; Dankort D; McMahon M; Mooi WJ; Peeper DS
Genes Dev; 2012 May; 26(10):1055-69. PubMed ID: 22549727
[TBL] [Abstract][Full Text] [Related]
6. Abl kinase regulation by BRAF/ERK and cooperation with Akt in melanoma.
Jain A; Tripathi R; Turpin CP; Wang C; Plattner R
Oncogene; 2017 Aug; 36(32):4585-4596. PubMed ID: 28368422
[TBL] [Abstract][Full Text] [Related]
7. ROS production induced by BRAF inhibitor treatment rewires metabolic processes affecting cell growth of melanoma cells.
Cesi G; Walbrecq G; Zimmer A; Kreis S; Haan C
Mol Cancer; 2017 Jun; 16(1):102. PubMed ID: 28595656
[TBL] [Abstract][Full Text] [Related]
8. Activated MEK cooperates with Cdkn2a and Pten loss to promote the development and maintenance of melanoma.
Yang H; Kircher DA; Kim KH; Grossmann AH; VanBrocklin MW; Holmen SL; Robinson JP
Oncogene; 2017 Jul; 36(27):3842-3851. PubMed ID: 28263969
[TBL] [Abstract][Full Text] [Related]
9. BRAFV600E cooperates with PI3K signaling, independent of AKT, to regulate melanoma cell proliferation.
Silva JM; Bulman C; McMahon M
Mol Cancer Res; 2014 Mar; 12(3):447-63. PubMed ID: 24425783
[TBL] [Abstract][Full Text] [Related]
10. PI3'-kinase inhibition forestalls the onset of MEK1/2 inhibitor resistance in BRAF-mutated melanoma.
Deuker MM; Marsh Durban V; Phillips WA; McMahon M
Cancer Discov; 2015 Feb; 5(2):143-53. PubMed ID: 25472943
[TBL] [Abstract][Full Text] [Related]
11. mTORC1 activation blocks BrafV600E-induced growth arrest but is insufficient for melanoma formation.
Damsky W; Micevic G; Meeth K; Muthusamy V; Curley DP; Santhanakrishnan M; Erdelyi I; Platt JT; Huang L; Theodosakis N; Zaidi MR; Tighe S; Davies MA; Dankort D; McMahon M; Merlino G; Bardeesy N; Bosenberg M
Cancer Cell; 2015 Jan; 27(1):41-56. PubMed ID: 25584893
[TBL] [Abstract][Full Text] [Related]
12. Differential AKT dependency displayed by mouse models of BRAFV600E-initiated melanoma.
Marsh Durban V; Deuker MM; Bosenberg MW; Phillips W; McMahon M
J Clin Invest; 2013 Dec; 123(12):5104-18. PubMed ID: 24200692
[TBL] [Abstract][Full Text] [Related]
13. Knockout of MDA-9/Syntenin (SDCBP) expression in the microenvironment dampens tumor-supporting inflammation and inhibits melanoma metastasis.
Das SK; Guo C; Pradhan AK; Bhoopathi P; Talukdar S; Shen XN; Emdad L; Subler MA; Windle JJ; Sarkar D; Wang XY; Fisher PB
Oncotarget; 2016 Jul; 7(30):46848-46861. PubMed ID: 27341128
[TBL] [Abstract][Full Text] [Related]
14. Aurora B is regulated by the mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK) signaling pathway and is a valuable potential target in melanoma cells.
Bonet C; Giuliano S; Ohanna M; Bille K; Allegra M; Lacour JP; Bahadoran P; Rocchi S; Ballotti R; Bertolotto C
J Biol Chem; 2012 Aug; 287(35):29887-98. PubMed ID: 22767597
[TBL] [Abstract][Full Text] [Related]
15. Fibronectin induction abrogates the BRAF inhibitor response of BRAF V600E/PTEN-null melanoma cells.
Fedorenko IV; Abel EV; Koomen JM; Fang B; Wood ER; Chen YA; Fisher KJ; Iyengar S; Dahlman KB; Wargo JA; Flaherty KT; Sosman JA; Sondak VK; Messina JL; Gibney GT; Smalley KS
Oncogene; 2016 Mar; 35(10):1225-35. PubMed ID: 26073081
[TBL] [Abstract][Full Text] [Related]
16. Deciphering the Role of Oncogenic MITFE318K in Senescence Delay and Melanoma Progression.
Bonet C; Luciani F; Ottavi JF; Leclerc J; Jouenne FM; Boncompagni M; Bille K; Hofman V; Bossis G; Marco de Donatis G; Strub T; Cheli Y; Ohanna M; Luciano F; Marchetti S; Rocchi S; Birling MC; Avril MF; Poulalhon N; Luc T; Hofman P; Lacour JP; Davidson I; Bressac-de Paillerets B; Ballotti R; Marine JC; Bertolotto C
J Natl Cancer Inst; 2017 Aug; 109(8):. PubMed ID: 28376192
[TBL] [Abstract][Full Text] [Related]
17. The Small GTPase ARF6 Activates PI3K in Melanoma to Induce a Prometastatic State.
Yoo JH; Brady SW; Acosta-Alvarez L; Rogers A; Peng J; Sorensen LK; Wolff RK; Mleynek T; Shin D; Rich CP; Kircher DA; Bild A; Odelberg SJ; Li DY; Holmen SL; Grossmann AH
Cancer Res; 2019 Jun; 79(11):2892-2908. PubMed ID: 31048499
[TBL] [Abstract][Full Text] [Related]
18. Distinct MAPK and PI3K pathway mutations in different melanoma types in Taiwanese individuals.
Gao HW; Tsai WC; Perng CL; Wang WM; Chiang CP
Eur J Dermatol; 2018 Aug; 28(4):509-518. PubMed ID: 30325319
[TBL] [Abstract][Full Text] [Related]
19. Concomitant Inhibition of PI3Kβ and BRAF or MEK in PTEN-Deficient/BRAF-Mutant Melanoma Treatment: Preclinical Assessment of SAR260301 Oral PI3Kβ-Selective Inhibitor.
Bonnevaux H; Lemaitre O; Vincent L; Levit MN; Windenberger F; Halley F; Delorme C; Lengauer C; Garcia-Echeverria C; Virone-Oddos A
Mol Cancer Ther; 2016 Jul; 15(7):1460-71. PubMed ID: 27196754
[TBL] [Abstract][Full Text] [Related]
20. Cell type specificity of PI3K signaling in Pdk1- and Pten-deficient brains.
Chalhoub N; Zhu G; Zhu X; Baker SJ
Genes Dev; 2009 Jul; 23(14):1619-24. PubMed ID: 19605683
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
